Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01931033
Other study ID # 2013-P-001548
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date October 2013
Est. completion date February 22, 2016

Study information

Verified date September 2023
Source Massachusetts General Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is an 8-week open-label trial testing oxytocin nasal spray (Syntocinon) as a treatment for social impairment in adolescents with autism spectrum disorders (ASD). We hypothesize that oxytocin nasal spray will be safe, tolerable, and effective in improving the core symptoms of autism spectrum disorders in adolescents ages 11-17.


Recruitment information / eligibility

Status Completed
Enrollment 8
Est. completion date February 22, 2016
Est. primary completion date February 22, 2016
Accepts healthy volunteers No
Gender All
Age group 11 Years to 17 Years
Eligibility Inclusion Criteria 1. Male and female outpatients ages 11-17 years 2. DSM-IV-TR PDD diagnosis of autistic disorder, Asperger's disorder, or PDD-NOS as established by clinical diagnostic interview and with the aid of the MGH ASD Symptom Checklist (MGH-ASD-SCL). 3. At least moderate severity of ASD impairment as measured by a raw score of =80 on the SRS and a severity score of =4 on CGI-PDD. 4. Participants and their parent/guardian must be able to speak and understand English sufficiently to comprehend the nature of the study and to allow for the completion of all study procedures required per protocol. 5. Subjects and their parent/guardian must be considered reliable reporters. 6. Each subject and their parent/guardian must understand the nature of the study and provide written informed assent/consent. 7. Subjects must be able to participate in mandatory blood draws. 8. Subjects with mood, anxiety, or disruptive behavior disorders will be allowed to participate in the study provided they do not meet any exclusionary criteria. Exclusion Criteria 1. IQ <85 2. Total lack of spoken language 3. DSM-IV-TR PDD diagnosis of Rett's disorder or childhood disintegrative disorder. 4. Clinically unstable psychiatric conditions or judged to be at serious suicidal risk as determined by evaluating investigator. 5. History of substance use (except nicotine or caffeine) within past 3 months 6. Serious, stable or unstable systemic illness including hepatic, renal, gastroenterological, respiratory, cardiovascular (including ischemic heart disease), endocrinologic, neurologic, immunologic, or hematologic disease. 7. Subjects with severe hepatic impairment (LFTs > 3 times ULN) and those with severely impaired renal function (eGFR < 30). 8. Pregnant or nursing females. 9. Known hypersensitivity to oxytocin. 10. Severe allergies or multiple adverse drug reactions. 11. A non-responder or history of intolerance to oxytocin, after treatment at adequate doses as determined by the clinician. 12. Subjects with significant nasal pathology (including atrophic rhinitis, recurrent nose bleeds, and history of hypophysectomy). 13. Investigator and his/her immediate family defined as the investigator's spouse, parent, child, grandparent, or grandchild. 14. Currently enrolled or recently participated (within the past 6 months) in a clinical trial of intranasal oxytocin.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Intranasal Oxytocin


Locations

Country Name City State
United States Massachusetts General Hospital Boston Massachusetts

Sponsors (1)

Lead Sponsor Collaborator
Massachusetts General Hospital

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in ASD Symptoms Social Responsiveness Scales 2 (SRS-2) Scales From Baseline to Week 8 Change in ASD symptoms as measured by change from baseline on the Social Responsiveness Scale 2 (SRS-2) scale.
The SRS-2 is a 65-item rating scale completed that is used to measure the severity of autism spectrum symptoms as they occur in natural settings. The SRS-2 School Age form is completed by a parent or guardian for patients ages 9-17 and the SRS-2 Adult Self-report is completed by patients ages 18-59. Total raw scores range from 0 to 195, with higher scores indicating increased symptom severity.
Week-8
Primary Number of Participants With =30% Reduction in SRS Raw Score and CGI Improvement Scores of = 2 at Week 8 The SRS-2 is a 65-item rating scale completed that is used to measure the severity of autism spectrum symptoms as they occur in natural settings. The SRS-2 School Age form is completed by a parent or guardian for patients ages 9-17 and the SRS-2 Adult Self-report is completed by patients ages 18-59. Total raw scores range from 0 to 195, with higher scores indicating increased symptom severity. The Clinical Global Impression Improvement scale (CGI-ASD-I) is a clinician rated measure of ASD improvement. Improvement scores range from 1 (very much improved) to 7 (very much worse). Week-8
See also
  Status Clinical Trial Phase
Active, not recruiting NCT02625116 - ELENA Cohort: A Long-term Longitudinal Study in a Pediatric Sample With Autism Spectrum Disorders
Not yet recruiting NCT06381856 - Improving Participation of Autistic Children and Adolescents in the Habilitation Process
Recruiting NCT02280746 - Gluten for Autism Spectrum Disorders N/A
Completed NCT01945957 - Brain Imaging of Intranasal Oxytocin Treatment in Autism Phase 1
Completed NCT01661855 - A Pilot Study of Riluzole Versus Placebo in the Treatment of Children and Adolescents With ASD Phase 2
Completed NCT01694667 - Omega-3 Fatty Acids for Hyperactivity Treatment in Autism Spectrum Disorder Phase 2
Completed NCT01592747 - Withdrawal Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified Previously Treated With Memantine Phase 2
Completed NCT01691066 - Pivotal Response Treatment for Infants At-Risk for Autism Spectrum Disorder N/A
Completed NCT01780090 - Handheld Technology for Speech Development in Students With Autism N/A
Active, not recruiting NCT01417026 - Intranasal Oxytocin and Learning in Autism Phase 2
Enrolling by invitation NCT01364818 - Brain Connectivity in Neurodevelopmental Disorders in Response to Treatment N/A
Completed NCT01695200 - Omega-3 Fatty Acids in Autism Spectrum Disorders Phase 4
Completed NCT02300597 - Internet-based Support for Young People With ADHD and Autism - a Controlled Study N/A
Not yet recruiting NCT00695812 - The Development of Younger Siblings of Children With Autism Now at 10 Years of Age N/A
Completed NCT01675414 - Understanding Gastrointestinal Conditions in Children With Autism Spectrum Disorder (ASD) N/A
Recruiting NCT05910502 - Project AFECT (Autism Family Empowerment Coaching and Training Program) N/A
Completed NCT02081027 - Pilot Study of Riluzole for Drug-Refractory Irritability in Autism Spectrum Disorders Early Phase 1
Completed NCT02797379 - The Development of a Psychoeducational Tool to Manage Anxiety in People With Autism Spectrum Disorders N/A
Terminated NCT01730079 - Near Infrared Spectroscopy in Children With Autism and ADHD
Completed NCT01603225 - Transcranial Direct Current Stimulation and Autism